Follow-up study of children with precocious puberty treated with cyproterone acetate

Journal of Epidemiology

Volumn 7, Issue 3, 1997, Pages 173-178

  Watanabe, Shaw ^a,b   Cui, Yadong ^b   Tanae, Ayako ^c   Tanaka, Toshiaki ^c   Fujimoto, Masatoshi ^d   Matsuo, Yoshitake ^e   Tachibana, Katsuhiko ^f   Yamasaki, Susumu ^g  

^a TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c National Children's Hospital

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^g Central Hospital

Author keywords

Adverse effects; Cyproterone acetate; Liver tumor; Precocious puberty

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; PROGESTERONE DERIVATIVE;

ADOLESCENT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; RISK;

ADENOMA, LIVER CELL; ADOLESCENT; ANDROGEN ANTAGONISTS; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; CYPROTERONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; PROGESTERONE CONGENERS; PUBERTY, PRECOCIOUS; RISK;

EID: 0031230106     PISSN: 09175040     EISSN: None     Source Type: Journal    
DOI: 10.2188/jea.7.173     Document Type: Article

References (23)

1. Editorial. Cyproterone acetate. Lancet 1976; i: 1003.
2. Meijer WH, Willemse PHB, Sleijfer T, et al. Hepatocellular damage by Cyproterone acetate. Eur J Cancer Clin Oncol 1986; 22(9): 1121-1122.
3. Levesque H., Trivalle C., Manchon N.D., et al. Fulminant hepatitis due to cyproterone acetate. Lancet 1989; 1(8631): 215-216.
4. Blake JC, Sawyer AM, Dooley JS, et al. Severer hepatitis caused by cyproterone acetate. Gut 1990; 31: 556-557.
5. Parys BT, Hamid S., and Thomson R.G.N. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991; 67: 312-313.
6. Pavlos E. D., Eliahu G., and Rappel C. Hepatitis due to Cyproterone Acetate. Eur J Cancer 1992; 28A(1): 1931-1932.
7. Riola R., Crino L., Carloni G., and Natalini G. Cyproterone acetate: hepatotoxicity and prostatic cancer treatment. Annals Oncology 1993; 4: 701-702.
8. Ohri SK, Caer JAR, Keane PF. Hepatocellular carcinoma and treatment with cyproterone acetate. Br J Urol 1991; 67: 213-221.
9. Kattan J., Apatz A., Culine S., et al. Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am J Clin Oncol Cancer Clin Trials 1994; 17(5): 390-392.
10. Watanabe S, Yamasaki S, Tanae A, et al. Three cases of hepatocellular carcinoma among cyproterone users. Lancet 1994; 344(8936): 1567-1568.
11. Rudiger T, Beckmann J, and Queiber W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol. Lancet 1995; 345(8937): 452-453.
12. The MILTS Collaborative Study Team. Multicentric international liver tumour study protocol of the casecontrol study on hepatocellular cancer. Pharmacoepidemiol Drug Safety 1996; 5: 173-186.
13. Topinka J, Andrae U, Schwarz LR, and Wolff T. Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. Carcinogenesis 1993; 14(3): 423-427.
14. Deml E, Schwarz LR, and Oesterle D. Initiation of enzymealtered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay. Carcinogenesis 1993; 14(6): 1229-1231.
15. Neumann I, Thierau D, Andrae U, et al. Cyproterone acetate Induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in gamma-gultamyltranspeptidase-positive cells. Carcinogenesis 1992; 13(3): 373-378.
16. Martelli A, Mattioli F, Fazio S, et al. DNA repair synthesis and DNA fragmentation in primary cultures of human and rat hepatocytes exposed to cyproterone acetate. Carcinogenesis 1995; 16(6): 1265-1269.
17. Werner s, Topinka J, Wolff T, and Schwarz LR. Accumulation and persisitence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver. Carcinogenesis 1995; 16(10): 2369-2372.
18. Kerdar RS, Baumann A, et al. Identification of 3alpha-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro. Carcinogenesis 1995; 16(8): 1835-1841.
19. Topinka J, Binkova B, Zhu HK, et al. DNA-damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. Carcinogenesis 1995; 16(7): 1483-1487.
20. Kasper P, Tegethoff K, and Mueller L. In vitro mutagenicity studies on cyproterone acetate using female rat hepatocytes for metabolic activation and as indicator cells. Carcinogenesis 1995; 16(10): 2309-2314.
21. Iqbal MJ, Wilkinson ML, Johnson PJ, and Williams R. Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. Br J Cancer 1983; 48: 791-796.
22. Nagasue N, Kohno H, Yamanoi A, et al. Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors. Cancer 1991; 67: 2501-2505.
23. Rabe T, Feldmann K, Heinemann L, and Runebaum B. Cyproterone acetate. Is it hepato- or genotoxic? Drug Safety 1996; 14: 25-38.